Submission of financial Results for the quarter ended 30th June, 2026.

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956 (NOVELIX | 536565 | INE314101036) Date: 13 August, 2026 The Deputy Manager Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400001. Sub: Unaudited Standalone Financial Results for the quarter ended 30" June, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref: Scrip Code: 536565 Serip Id: NOVELIX Respected Sir/ Madam, Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 13" August, 2026 have considered and approved, the unaudited standalone Financial Results of the company for the quarter ended 30" June, 2026 along with the limited review report of the auditors thereon. The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 05:35 p.m. (IST). The aforesaid information is also available on the website of the Company www.novelixpharma.com We request you to take the aforesaid information on record for dissemination through your website. Thanking you, Yours Faithfully, Venkateshwarlu Pu 1 (Whole-time director) DIN: 02076871 Novelix Pharmaceuticals limited (Formerly Known as TRIMURTHI LIMITED) H No: 3-6-237/610, Flat No: 610, 6™ Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com www.novelixpharma.com INDIA CVS Balachandra Rao & Co., Chartered Accountants Limited Review Report on Standalone Unaudited Quarterly Financial Results of Novelix Pharmaceuticals Limited (Formerly Trimurthi Limited) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 The Board of Directors Novelix Pharmaceuticals Limited (Formerly known as Trimurthi Limited) We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of Novelix Pharmaceuticals Limited (Formerly known as Trimurthi Limited) for the quarter ended on 30" June, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, (the “Listing Regulations’). This statement which is the responsibility of the Company’s Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For CVS Balachandra Rao & Co., Chartered Accountants Membership Number:204580 UDIN: 26204580HBVZEG4518 Date: 13/08/2025 Place: Hyderabad 029, Telangan: Dot & L 1031; etNo: 203. Sanatana ©Et er9n8a4l,9 0S 3t 5r 3e 1et 5 ,N o9:0119,0 6H 2i 4m 4a 5y 5a l Nagar. Hyderabad - 500 elangana sbala@gmail com, cvsbalab7@gmai&l .Wcebosimt,e :w ww.cabrc.n Branch MCGBDCZ%V 11-3:?798_ 2nd Floor, Tatakulavari Street, Samarang Chowk, Vijayawada - 520 001 AP e 4H No. 16-2/20/3, Sainiranjion Colony, Dogguvanipalem, Pendurthy- 531 173. Vishakapatnam, A P. Novelix Phavmaceuticals limited (Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956 (NOVELIX | 53|6 INE531461010536) STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30™ JUNE 2026 Rs. (In Lakm S: Particulars 3 Months Preceding 3 | Corresponding | Year ended ended Months 3 Months ended ended in previous year 30/06/2026 | 31/03/2026 30/06/2025 31/03/2026 Unaudited Audited Unaudited Audited 1 | Revenue a) From operations 3,691.39 2,519.36 2,235.12 13,230.62 b) Other Income 0.12 (0.00) - 3.26 Total Revenue 3,691.51 2,519.36 2,235.12 13,233.88 2 Expenses (a) Cost of Material Consumed - - - - (b) Purchases of stock-in- trade 3,193.39 3,284.31 2,249.50 14,030.37 (c) Change in inventories of finished goods, work-in- progress and stock-in-trade 292.95 (994.40) (71.64) (1,358.89) (d) Employees Benefits expenses 19.66 23.90 16.46 71.83 (e) Finance Cost 11.54 - = N (f) Depreciation amortization expenses 7.00 4.61 1.10 10.11 (g) Other Expenses 55.44 77.65 22.76 140.03 Total Expenses 3,579.98 2,396.07 2,218.18 12,893.45 3 Profit from ordinary activities before exceptonal Items (1 - 2) 111.53 123.29 16.94 340.43 4 Exceptional Items - Income/ (Expenses) a - = - 5 Profit from ordinary activities before tax (3 - 4) 111.53 123.29 16.94 340.43 6 | Tax Expenses (a) Current Tax 25.64 32.65 3.54 83.02 (b) Deferred Tax (32.00) (0.56) 2.70 1.75 7 Profit/(Loss) for the period (5-6) 117.89 91.19 10.70 255.66 8 A (i) Items that will not be reclassified to profit or loss (net of tax) - - = (ii) Income Tax relating to items that will not be reclassified to profit or loss - - - Novelix Pharmaceuticals limited (Formerly Known as TRIMURTHI LIMITED) H No: 3-6-237/610, Flat No: 610, 6™ Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals @gmail.com www.novelixpharma.com Novelix Phavmaceuticals limited (( NFo Or Vm Ee Lr Ily |T 5R 3I 6M 5U 65R T H INI 3L 1I 4M 1I 0T E 0D 3) C IN: L67120TG1994PLC018956 B (i) Items that will not be reclassified to profit or loss (net of tax) (i) Income Tax relating to items that will not be reclassified to profit or loss - - - - 9 Total Comprehensive Income, net of tax (7 + 8) 117.89 91.19 10.70 255.66 10 | Paid up equity share capital (Face Value of Rs.10/- each) 2,389.50 2108.50 2,389.50 2108.50 11 | Earning per share of Rs.10/- each) not annualised (a) Basic 0.49 043 0.09 121 (b) Diluted 0.49 0.32 0.11 175 NOTES: 1 The above Unaudited Financial Results of the company for the quarter ended June 30" 2026 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on August 13, 2026. 2 The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). 3 | Figuresin respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period. a4 These financial results have been prepared in accordance with Indian Accounting Standards (‘IND AS’) prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obli [Showing first 8,000 characters — download PDF for full document]